Virbac share falls 5.5%, lagging the SBF 120 after its results
Despite half-yearly results published yesterday evening that confirm solid organic growth, the stock of the Carros-based veterinary laboratory is declining sharply during trading and breaking through an important technical threshold. The SFAF meeting dedicated to financial and strategic information for the first half is taking place today, in a context of pressure on the Paris market.
A 302 € support lost during trading, the share remains below its three moving averages
Virbac is down 5.25% at 298 € during trading, making it the laggard of the SBF 120, an index that itself is declining 0.73%. The price has broken through the 302 € support and remains below it, at 301.50 € at its low, widening a gap of nearly 7% below the MA20 at 319.63 €. The distance to the longer-term moving averages is even more pronounced: the MA50 at 328.11 € is 9.18% above the current price, while the MA200 at 346.96 € is more than 14% away.
This triple bearish gap paints a picture of prolonged pressure, which the RSI at 44 does not yet contradict: the indicator remains in neutral territory, with no sign of selling exhaustion for now. The next major resistance is set at 345 €, which is the zone of longer-term moving averages.
CIC Market Solutions maintains its buy opinion with a target of 400 €, representing 34% of potential
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
While the share is declining significantly, CIC Market Solutions confirmed today its analyst opinion to buy Virbac, with an unchanged price target of 400 €. At the current price of 298 €, this target represents an upside potential of approximately 34%. The half-yearly publication released on September 17, 2026 — organic growth of 7.4% and annual targets confirmed in the upper end of the range — was not enough to stop the selling pressure.
The monthly decline now stands at 9.42%, in line with a downward trend that has been underway for several weeks. The SFAF meeting today, dedicated to financial and strategic information for the first half, represents the key event for the group; the share remains worth monitoring as it touches the 298 € threshold, which represents a near-term floor following the loss of the 302 € support.
SectorPharmacie et biotechnologies›Pharmacie, vaccins et santé animale
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 9M 2026
Key reported figures
Revenue: 1 168 millions d'euros
Quarterly revenue: 1 168 millions d'euros
Guidance from the release
Notre solide performance à fin septembre 2026 nous permet de viser le haut de notre fourchette initiale de croissance du chiffre d'affaires
Risks mentioned
Effets de change défavorables impactant la croissance réelle (croissance réelle +5,9% vs +7,9% à taux constants)
Pression concurrentielle persistante sur les vaccins porcins en Asie de l'Est et pressions tarifaires au segment Animaux d'élevage
Exposition au Moyen-Orient et suivi des tendances inflationnistes (énergie) malgré anticipation d'impacts limités
Opportunities identified
Croissance soutenue des plateformes Supercharge (+11% environ) couvrant petfood, reproduction, dentaire, mobilité, otologie, endocrinologie et ruminants
Intégration fluide de Thyronorm dans la franchise d'endocrinologie avec contribution de +1 point de croissance et +0,5 point d'Ebit ajusté
Redémarrage réussi de la production du contrat majeur de façonnage en Amérique du Nord (juillet 2026) après contrainte réglementaire temporaire
Outlook / guidance
Expected revenue: 1 575 millions d'euros
Management commentary: « Bien que nos perspectives pour l'ensemble de l'année 2026 restent inchangées, notre solide performance à fin septembre (croissance de +7,9%) nous permet de viser la borne haute de notre fourchette de croissance du chiffre d'affaires de 5,5 % à 7,5 % à PCC »
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
